ALPMF News and Press, Astellas Pharma Inc From 12/20/22

The US FDA has accepted supplemental Biologics License Applications from Merck ( NYSE: MRK ), Seagen ( NASDAQ: SGEN ), and Astellas ( OTCPK:ALPMF )( OTCPK:ALPMY ) for a combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) for urotheli...

Astellas Pharma Inc. (ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 04:00 a.m. ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scientific Officer Minoru Kikuoka - Chief Financial Officer Tadaaki ...

Astellas Pharma press release ( OTCPK:ALPMF ): 1H GAAP EPS of ¥65.78. Revenue of ¥762.18B (+17.0% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥65.78, revenue of ¥762.18B

Summary Twist Bioscience share price has fallen by 50% since the beginning of 2022. Management thinks DNA data storage could be $2 billion market for the company, aided by early mover advantage and investment in IP. Twist Bioscience recently raised full-year revenue guidance, ...

Summary Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has...

A jury has ordered Eli Lilly ( NYSE: LLY ) to pay $61M in a whistleblower case that accused the drugmaker of making false claims about pricing under Medicaid's drug pricing program, Bloomberg reported. The suit was filed in 2014 by whistleblower Ronald J. Streck wh...

Astellas Pharma ( OTCPK:ALPMF ) announced the appointment of Dr. Tadaaki Taniguchi as the company's new chief medical officer to succeed Bernhardt Zeiher, effective Oct. 1, 2022. The company noted: " Taniguchi is an internationally trained surgeon in the field o...

While the Tweedy, Browne Funds were not immune to the challenges during the quarter, they, for the most part, held up much better than their benchmark international and global indices. It is impossible, of course, to know whether markets have hit bottom, but if the past is prologue co...

Astellas Pharma, Inc. (ALPMF) Q1 2022 Earnings Conference Call August 01, 2022 03:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Minoru Kikuoka - CFO Yukio Matsui - CCO Bernie Zeiher - CMO Conference Call Particip...

Astellas Pharma press release ( OTCPK:ALPMF ): Q1 GAAP EPS of ¥25.12. Revenue of ¥381.79B (+17.1% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥25.12, revenue of ¥381.79B